With the recent discovery of the BRAF-V600E mutation in a high prevalence of LCH cases (50%–60%), the disease was recognized as cancer with marked inflammation.1, 2 Recent studies suggest a clinical correlation between the presence of the mutation and the recurrence and severity of the disease.3 Here, BRAF is linked to Langerhans cell histiocytosis.